Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis |
| |
Institution: | 1. Department of Dermatology, The First Hospital of China Medical University, Shenyang 110001, China;2. Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, China;1. Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China;2. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China;3. Department of Preventive Medicine, the Medicine School of Hunan Normal University, Changsha, Hunan, China;4. Guangdong Provincial Dermatology Hospital, Guangzhou, Guangdong, China;5. Shandong Provincial Hospital of Dermatology, Jinan, Shandong, China;6. Department of Dermatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China;7. Shanghai Dermatology Hospital, Shanghai, China;8. Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Central South University, Changsha, Hunan, China;9. Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China;1. Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland;2. Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznań, Poland;1. Department of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagakicho, Suzuka, Mie 513-8670, Japan;2. R&D Department, Daiichi Sankyo healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo 103-8234, Japan |
| |
Abstract: | Rosacea is a chronic inflammatory cutaneous disease characterized by immune system anomalies and vascular hyperreactivity. Recently, therapy of rosacea has improved substantially with the approval of Tranexamic acid (TXA), an antifibrinolytic agent. However, we know little about the underlying mechanism. In this study, we evaluated the effects of TXA and its molecular mechanism on rosacea by using LL37-induced mouse model and HaCaT cell model. Rosacea-like symptoms including skin erythema and histopathological alterations, as well as the elevated pro-inflammatory cytokines (IL-6 and TNFα) and MMP9 expression were significantly ameliorated by TXA treatment. In addition, TXA reduced the expression levels of innate immune gene (TLR2, KLK5 and Camp) and neutrophils relative gene in rosacea-like lesion. For adaptive immune, CD4+ T cell infiltration and the gene expression of Th cytokines and chemokines were regulated by TXA in skin lesion. Furthermore, the anti-inflammatory effects of TXA were associated with the inhibition of TLR2, pro-inflammatory cytokines (IL-6 and TNFα) and chemokines (CCL10) expression in LL37-activated HaCaT cells. Finally, TXA repressed the angiogenesis by reducing the number of CD31+ cell and downregulating the expression levels of VEGF in rosacea. In conclusion, our finding defines a treatment mechanism by which TXA ameliorates rosacea symptoms by regulating the immune response and angiogenesis. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|